Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06046222 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status changed: Recruiting → Active, Not Recruiting Primary completion pushed from Jun 2026 to Dec 2026 · Completion pushed from Jul 2026 to Dec 2026 · Site details revised at 34 of 34 sitesv9 Show 3 more changesShow less
    • Primary completion pushed from Jun 2026 to Dec 2026
    • Completion pushed from Jul 2026 to Dec 2026
    • Site details revised at 34 of 34 sites
  2. Site details revised at 3 of 34 sitesv8
  3. Study sites: 28 to 34 Eligibility criteria revised · Study description revisedv7 Show 2 more changesShow less
    • Eligibility criteria revised
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 23 to 28v6
  5. Study sites: 16 to 23v5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Apr 2025 to Jun 2026 Study sites: 10 to 16 · Completion date: May 2025 to Jul 2026 · Eligibility criteria expanded, about 15 wordsv4 Show 3 more changesShow less
    • Study sites: 10 to 16
    • Completion date: May 2025 to Jul 2026
    • Eligibility criteria expanded, about 15 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 4 to 10v3
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 4 · Start date changed from estimate of Sep 2023 to Dec 20, 2023v2 Show 2 more changesShow less
    • Study sites: 0 to 4
    • Start date changed from estimate of Sep 2023 to Dec 20, 2023
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.
Trial Details
NCT Number NCT06046222
Lead Sponsor NS Pharma, Inc.
Collaborators: Nippon Shinyaku Co., Ltd.
Conditions Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov